Description
Anti-CEACAM8 Antibody, Non-Fucosylated (BioBet-169ZP) is a mouse monoclonal IgG1, κ antibody against CEACAM8. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Bone marrow scintigraphy
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CEACAM8 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CEACAM8
Full Name
Carcinoembryonic Antigen Related Cell Adhesion Molecule 8
Background
CEACAM8 (Carcinoembryonic Antigen Related Cell Adhesion Molecule 8) is a Protein Coding gene.
Diseases associated with CEACAM8 include Endocarditis and Shwartzman Phenomenon.
Among its related pathways are Response to elevated platelet cytosolic Ca2+ and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers.
An important paralog of this gene is CEACAM6.
Alternative Names
Besilesomab; scintimun; 537694-98-7; BW 250/183; CEACAM8; carcinoembryonic antigen-related cell adhesion molecule 8; CGM6; CD66b; CD67 antigen; carcinoembryonic antigen CGM6; non-specific cross-reacting antigen NCA-95; carcinoembryonic antigen gene family member 6;
Gene ID
1088
UniProt ID
P31997
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with CEACAM8 include Hemoglobinuria and Paroxysmal Nocturnal Hemoglobinuria.
Related Pathways
Its related pathways are Degradation of the extracellular matrix and Cell surface interactions at the vascular wall.
Function
Cell surface glycoproteins that play a role in cell adhesion (PubMed:8776764, PubMed:2022629, PubMed:11590190). Cell adhesion molecules that mediate heterophils and other carcinogenic embryonic antigens, such as CEACAM6 (PubMed:8776764, PubMed:2022629, PubMed:11590190). The heterophilic interaction with CEACAM8 occurs in activated neutrophils (PubMed:8776764).
Post-translational modifications
1.Glycosylated 2.Glycosylation at Asn104, Asn111, Asn115, Asn152, Asn173, Asn197, Asn224, Asn256, Asn274, Asn288, and Asn309 3.Modification sites at PhosphoSitePlus 4.Glycosylation from GlyConnect
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, κ
Antibody Clone
BioBet-169ZP
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Mouse antibody to Human CEACAM8. Besilesomab (trade name Scintimun) is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m. It is used to detect inflammatory
Antibody Indication
Bone marrow scintigraphy
